Naltrexone hydrochloride
SIGMA/N3136
Synonym: Naltrexone HCl
CAS Number: 16676-29-2
Empirical Formula (Hill Notation): C20H23NO4 · HCl
Molecular Weight: 377.86
EC Number: 240-723-0
MDL Number: MFCD00069324
Linear Formula: C20H23NO4 · HCl
Product Type: Chemical
| form | powder |
| InChI | 1S/C20H23NO4.ClH/c22-13-4 |
| InChI key | RHBRMCOKKKZVRY-ITLPAZOVSA |
| originator | Novartis |
| Quality Level | 100 ![]() |
| SMILES string | Cl.Oc1ccc2C[C@H]3N(CC[C@@ |
| storage temp. | 2-8°C |
| Application: | Naltrexone hydrochloride has been used: • as an opioid antagonist, to analyse its effect on ethanol preference using Caenorhabditis elegans as a model • to determine its effectiveness in reducing the preference for substance of abuse (SOA) like nicotine and cocaine using Caenorhabditis elegans as a model • in the preparation of combinatorial drug, PXT3003 for treating Charcot-Marie-Tooth disease 1A (CMT1A) transgenic rat model Pmp22 |
| Biochem/physiol Actions: | Competitive antagonist for μ, κ, δ, and σ-opioid receptors; has greater oral efficacy and longer duration of action than naloxone. |
| Features and Benefits: | This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264 - P270 - P301 + P312 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 22-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


